To ask the Scottish Government, in light of the announcement by NHS England in July 2025 that the triple combination medicine vanzacaftor–tezacaftor–deutivacaftor (Alyftrek) is to be made available to patients with cystic fibrosis, including some with rare forms of the disease who will now be eligible for a triple therapy for the first time, whether such therapy will be available by NHS Scotland, and, if so, by what date...